Stents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group

C Lotan1, Y Rozenman, A Hendler

  • 1Hadassah University Hospital, Jerusalem, Israel.

European Heart Journal
|November 10, 2000
PubMed

Insights

Coronary stenting significantly reduces restenosis and reocclusion after balloon angioplasty for chronic total occlusions. While effective, diffuse in-stent restenosis necessitates careful stent selection and placement.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Medicine

Background:

  • Chronic total occlusions (CTO) of coronary arteries present a significant challenge.
  • Percutaneous transluminal coronary angioplasty (PTCA) for CTO has a high restenosis rate.
  • Coronary stenting is explored as a method to reduce restenosis and reocclusion post-PTCA.

Purpose of the Study:

  • To evaluate if coronary stenting improves outcomes after successful balloon angioplasty for CTO.
  • To compare restenosis and reocclusion rates between PTCA alone and PTCA with stenting in CTO.

Main Methods:

  • A multicentre randomized study involving 96 patients with CTO.
  • Patients with optimal PTCA results were randomized to either no further treatment or stent implantation (AVE microstent).
  • Clinical follow-up at 1, 3, and 6 months, with coronary angiography at 6 months or earlier if indicated.

Main Results:

  • Stent implantation was successful in all patients with no major complications.
  • Binary restenosis rates were significantly lower in the stent group (42.1%) compared to the PTCA group (70.9%) (P=0.034).
  • Reocclusion rates were 7.9% in the stent group versus 16.1% in the PTCA group. Restenosis patterns differed: focal in PTCA, diffuse in-stent in the stented group.

Conclusions:

  • Coronary stenting significantly decreases restenosis and reocclusion rates in CTO.
  • The diffuse nature of in-stent restenosis suggests careful consideration of stent length and placement at the occlusion site.
Abstract

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...